An open-label study of single-dose COMP360 psilocybin for post-traumatic stress disorder: safety, tolerability, and secondary efficacy outcomes

psilocybin (COMP360) - Compass Pathways

N. Mcgowan 1; J. Rucker 2; R. Yehuda 3; M. Agrawal 4; H. Simmons 5; S. Das 6; G. Goodwin 7

Oct 10, 2025